MedPath

Prevention of Vitamin D Deficiency

Not Applicable
Completed
Conditions
Vitamin D Deficiency
Interventions
Dietary Supplement: Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day
Registration Number
NCT00494104
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Brief Summary

Breastfed infants living in a northern location (41 degrees N) are at high risk of vitamin D deficiency during winter. This trial is designed to determine how much supplemental vitamin D breastfed infants need to receive in order to remain free of vitamin D deficiency

Detailed Description

It is increasingly being recognized that infants and children living at northern latitudes are at risk of vitamin D deficiency, especially if their skin is darkly pigmented. The study by the PI (Pediatrics 2006;118:603) was the first to demonstrate that infants with light skin pigmentation living at 41 degrees north are at risk of vitamin D deficiency. During winter (December - April) a full 78% of infants were vitamin D deficient if they did not receive vitamin D from an external source. Very few breastfed babies are currently receiving supplemental vitamin D. The recommended dose is 200 IU/day. However, there are questions about the adequacy of this dose of vitamin D for the prevention of vitamin D deficiency. The present trial is designed to determine whether a dose of 200 IU/day is effective or whether doses of 400 IU/day, 600 IU/day or 800 IU/day are required to prevent vitamin D deficiency reliably.

The trial is a randomized, prospective double-blind trial in which breastfed infants will receive 200 IU/day or 400 IU/day or 600 IU/day or 800 IU/day from 1 to 9 months of age. There will not be a placebo control group. Infants will be followed through 12 months of age. Normal term infants (birth weight \>2500 g) who are born in June through November will be enrolled and randomized at 1 month of age. They will visit the study center at monthly intervals and will have capillary blood drawn at select ages. At 2 months and again in March or April whole body mineral content will be determined by DEXA. Infants will not be permitted to receive formula until 9 months of age. They may receive complementary foods beginning at 4 months of age. Vitamin D supplements will be weighed before dispensing and again when the empty and half-empty containers are returned. Study endpoints will be blood parameters and bone mineral content determined at the end of winter, i.e., between March and May 15. Blood parameters include 25-OHD, parathyroid hormone, calcium, alkaline phosphatase, osteocalcin, N-telopeptide, ferritin and transferrin receptor. 180 infants will be enrolled at 1 month of age in the expectation that 48 per group will complete the trial to at least 9 months of age.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
398
Inclusion Criteria
  • Term infant
  • No major congenital malformations
  • Less than one month old
  • Breastfed, no other foods
Exclusion Criteria
  • Formula feeding
  • Premature birth

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
400 IU/day Vitamin DVitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day400 IU/day Vitamin D
600 IU/day Vitamin DVitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day600 IU/day Vitamin D
800 IU/day Vitamin DVitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day800 IU/day Vitamin D
200 IU/day Vitamin DVitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day200 IU/day Vitamin D
Primary Outcome Measures
NameTimeMethod
Plasma concentrations of 25-hydroxyvitamin D, parathyroid hormone, alkaline phosphataseend of winter
Secondary Outcome Measures
NameTimeMethod
whole body mineral content by DEXAend of winter

Trial Locations

Locations (1)

MTF, 2501 Crosspark Rd

🇺🇸

Coralville, Iowa, United States

© Copyright 2025. All Rights Reserved by MedPath